NBL1 Polyclonal antibody
NBL1 Polyclonal Antibody for WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, ELISA
Conjugate
Unconjugated
验证数据展示
经过测试的应用
Positive WB detected in | mouse colon tissue |
推荐稀释比
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:200-1:1000 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
12069-1-AP targets NBL1 in WB, ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Applications | WB, ELISA Application Description |
Tested Reactivity | human, mouse, rat |
Immunogen | NBL1 fusion protein Ag2706 种属同源性预测 |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Full Name | neuroblastoma, suppression of tumorigenicity 1 |
Synonyms | D1S1733E, DAN, DAN domain family member 1, DAND1, NB, NBL1, NO3, Protein N03, Zinc finger protein DAN |
Calculated Molecular Weight | 180 aa, 19 kDa |
Observed Molecular Weight | 19 kDa |
GenBank Accession Number | BC012037 |
Gene Symbol | NBL1 |
Gene ID (NCBI) | 4681 |
RRID | AB_10638604 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
UNIPROT ID | P41271 |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
NBL1 (neuroblastoma suppression of tumorigenicity 1), also named as DAN, is the founding member of the DAN subfamily. It was originally identified as a putative tumor suppressor gene in a transformed fibroblast rat model (PMID: 9516839), whereby it was significantly down-regulated in v-src-transformed rat fibroblasts. The MW of this protein is 19 kDa, and this antibody specially recognises the 19 kDa protein.
实验方案
Product Specific Protocols | |
---|---|
WB protocol for NBL1 antibody 12069-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |